基于治疗前PET表征器官内异质性预测PSMA靶向放射性药物治疗的体素级剂量学
回顾性纳入23例接受[177Lu]Lu-PSMA I&T RPT的转移性去势抵抗性前列腺癌患者共48个治疗周期,比较治疗前PET与治疗后SPECT/CT在肾、肝、脾的器官内分布差异,并探索器官剂量引导直接投影与深度学习两种体素级剂量预测策略;深度学习方法体素级归一化均方根误差更低(0.79±0.27% vs 1.11±0.57%,P<0.05),肾DVH预测R²=0.92。
要点
- 治疗前PET与治疗后剂量图在肾、肝、脾存在器官内分布不一致,相关性中等(肾r=0.77、肝r=0.5、脾r=0.58,P<0.025)。
- 药代动力学模拟提示器官内药代异质性可能解释上述不一致。
- 深度学习方法体素级归一化均方根误差0.79±0.27%,优于器官剂量引导投影的1.11±0.57%(P<0.05)。
核心结论
- 器官内药代动力学异质性可能使治疗前剂量学预测复杂化。
- 深度学习有潜力弥合这一差距,用于治疗前体素级异质性剂量图预测。
研究设计与样本
- 回顾性纳入23例接受[177Lu]Lu-PSMA I&T RPT的转移性去势抵抗性前列腺癌患者。
- 选取48个治疗周期,均有治疗前PET显像和至少3次治疗后SPECT/CT显像。
- 比较肾、肝、脾的PET示踪剂分布与RPT剂量分布,并行药代动力学模拟。
- 探索两种治疗前体素级剂量预测策略:器官剂量引导直接投影和基于深度学习的分布预测。
- 采用物理指标、剂量体积直方图分析和恒等图评估预测的吸收剂量图。
主要发现
- PET显像与剂量图在器官内呈现不一致模式,肾(r=0.77)、肝(r=0.5)、脾(r=0.58)存在中等相关性(P<0.025)。
- 模拟结果提示器官内药代动力学异质性可能解释这种不一致。
- 基于深度学习的方法相对于真实剂量图的平均体素级归一化均方根误差为0.79±0.27%,优于器官剂量引导投影的1.11±0.57%(P<0.05)。
- DVH分析显示预测准确性良好(肾R²=0.92)。
- 与器官剂量方法的理论最优结果相比,深度学习模型提高了恒等图拟合线的平均斜率(肝为199%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Treatment planning through the diagnostic dimension of theranostics provides insights into predicting the absorbed dose of RPT, with the potential to individualize radiation doses for enhancing treatment efficacy. However, existing studies focusing on dose prediction from diagnostic data often rely on organ-level estimations, overlooking intra-organ variations. This study aims to characterize the intra-organ theranostic heterogeneity and utilize artificial intelligence techniques to localize them, i.e. to predict voxel-wise absorbed dose map based on pre-therapy PET. METHODS: 23 patients with metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA I&T RPT were retrospectively included. 48 treatment cycles with pre-treatment PET imaging and at least 3 post-therapeutic SPECT/CT imaging were selected. The distribution of PET tracer and RPT dose was compared for kidney, liver and spleen, characterizing intra-organ heterogeneity differences. Pharmacokinetic simulations were performed to enhance the understanding of the correlation. Two strategies were explored for pre-therapy voxel-wise dosimetry prediction: (1) organ-dose guided direct projection; (2) deep learning (DL)-based distribution prediction. Physical metrics, dose volume histogram (DVH) analysis, and identity plots were applied to investigate the predicted absorbed dose map. RESULTS: Inconsistent intra-organ patterns emerged between PET imaging and dose map, with moderate correlations existing in the kidney (r = 0.77), liver (r = 0.5), and spleen (r = 0.58) (P < 0.025). Simulation results indicated the intra-organ pharmacokinetic heterogeneity might explain this inconsistency. The DL-based method achieved a lower average voxel-wise normalized root mean squared error of 0.79 ± 0.27%, regarding to ground-truth dose map, outperforming the organ-dose guided projection (1.11 ± 0.57%) (P < 0.05). DVH analysis demonstrated good prediction accuracy (R2 = 0.92 for kidney). The DL model improved the mean slope of fitting lines in identity plots (199% for liver), when compared to the theoretical optimal results of the organ-dose approach. CONCLUSION: Our results demonstrated the intra-organ heterogeneity of pharmacokinetics may complicate pre-therapy dosimetry prediction. DL has the potential to bridge this gap for pre-therapy prediction of voxel-wise heterogeneous dose map.
引用
- Xue S, Gafita A, Zhao Y, et al. Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics. Eur J Nucl Med Mol Imaging. 2024. PMID: 38724653. doi:10.1007/s00259-024-06737-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。